Walgreens is expanding its specialty pharmacy services and renaming AllianceRx Walgreens Pharmacy as Walgreens Specialty Pharmacy.
Walgreens announced today that it was creating a new, more comprehensive specialty pharmacy business that will include gene and cell services.
The company, long known for its retail pharmacies, said in a news release that it is opening an 18,000-square-foot center in Pittsburgh to house its cell and gene services.
The company said it was retiring the name AllianceRx Walgreens Pharmacy and the newly dubbed Walgreens Specialty Pharmacy will also include four central specialty dispensing pharmacies, almost 300 community-based specialty pharmacies and more than 1,500 specialty-trained pharmacies.
“With approximately $24 billion in annual enterprise specialty revenue, Walgreens Specialty Pharmacy is the largest independent provider that offers the industry's most robust specialty capabilities not vertically aligned with a pharmacy benefit manager,” said Rick Gates, chief pharmacy officer, in a news release.
Effective Aug. 1, 2024, AllianceRx Walgreens Pharmacy will become Walgreens Specialty Pharmacy, according to the news release. The company said patients and Walgreens community-based specialty pharmacies now have access to clinicians with key disease state expertise, nutritionists and care nurses. Gates said this will help patients to identify patient assistance that can help with their care.
This is just the latest in series of name and ownership changes for the specialty pharmacy business. In 2017, Walgreens and Prime Therapeutics, a pharmacy benefit manager (PBMs) owned by Blues plans, formed AllianceRx Walgreens Prime. In 2022, when Walgreens became the full owner of the specialty pharmacy business, the name changed to AllianceRx Walgreens Pharmacy.
Additionally, Walgreens owns Shields Health Solutions, a specialty pharmacy that distributes medications to hospitals. Walgreens started investing in Shields in 2019 and fully acquired the business last year, according to the Shields website. The company has seen “consistent growth” through Shields, the news release said.
FDA Updates for Week of April 29, 2024: Full Approval for Tivdak
May 4th 2024The FDA made several approvals this week, including converting Tivdak’s accelerated approval to full approval for cervical cancer and approvals for a high-concentration formulation of Cyltezo, Xolremdi for an ultra rare immune disorder and Libervant Film for epilepsy in young children.
Read More
Older Adults' Concerns Highlight Healthcare Cost and Access Challenges
May 3rd 2024The University of Michigan National Poll on Healthy Aging recently conducted the survey focusing on the concerns of adults aged 50 and above regarding various health-related issues in their communities.
Read More
DC Roundtable: Patrick Cooney of The Federal Group Drops the Latest on PBM Legislation in Washington
April 11th 2024In this episode of "DC Roundtable," Peter Wehrwein, managing editor of Managed Healthcare Executive, spoke with Patrick Cooney, president of The Federal Group, a lobbying and strategic planning firm in Washington, D.C., about recent developments in Washington concerning PBMs.
Listen